Overview
Familial apolipoprotein C-II (apo C-II) deficiency is a very rare inherited disorder of fat metabolism. It is also known as familial chylomicronemia due to apo C-II deficiency or hyperlipoproteinemia type Ib. In this condition, the body cannot properly break down certain fats (triglycerides) in the blood because it lacks a key protein called apolipoprotein C-II. This protein normally activates an enzyme called lipoprotein lipase, which is responsible for clearing fat particles (chylomicrons and very low-density lipoproteins) from the bloodstream. Without functioning apo C-II, triglyceride levels become extremely high, often reaching thousands of milligrams per deciliter. The hallmark symptom is recurrent episodes of acute pancreatitis, which causes severe abdominal pain and can be life-threatening. Other common signs include eruptive xanthomas (small yellowish bumps on the skin caused by fat deposits), lipemia retinalis (a milky appearance of the blood vessels in the eye), and hepatosplenomegaly (enlarged liver and spleen). The blood itself may appear milky or creamy due to the extremely high fat content. Treatment centers on a very strict low-fat diet, typically limiting dietary fat to 10-20 grams per day. There are currently no widely approved drug therapies that specifically correct the underlying protein deficiency, though newer gene therapies and antisense treatments for related conditions are being studied. Managing and preventing pancreatitis episodes is the primary goal of care. With careful dietary management, many patients can reduce the frequency of dangerous complications.
Also known as:
Key symptoms:
Severe abdominal pain from pancreatitisExtremely high triglyceride levels in the bloodMilky or creamy-looking bloodSmall yellowish bumps on the skin (eruptive xanthomas)Enlarged liverEnlarged spleenMilky appearance of blood vessels in the back of the eyeNausea and vomitingLoss of appetiteFatty deposits around tendons or jointsAbdominal bloating or discomfortFatigue
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Variable
Can begin at different ages, from infancy through adulthood
FDA & Trial Timeline
1 eventArrowhead Pharmaceuticals — PHASE3
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Familial apolipoprotein C-II deficiency.
1 clinical trialare actively recruiting — trials can provide access to cutting-edge therapies.
View clinical trials →Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Familial apolipoprotein C-II deficiency.
Community
No community posts yet. Be the first to share your experience with Familial apolipoprotein C-II deficiency.
Start the conversation →Latest news about Familial apolipoprotein C-II deficiency
No recent news articles for Familial apolipoprotein C-II deficiency.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.How low should my daily fat intake be, and can a dietitian help me plan meals?,What are the warning signs of pancreatitis, and when should I go to the emergency room?,Should my family members be tested for this condition or carrier status?,Are there any newer treatments or clinical trials I should know about?,How often should I have my triglyceride levels checked?,Do I need to take vitamin supplements because of my restricted diet?,What should I do if I accidentally eat a high-fat meal — is there an emergency plan?
Common questions about Familial apolipoprotein C-II deficiency
What is Familial apolipoprotein C-II deficiency?
Familial apolipoprotein C-II (apo C-II) deficiency is a very rare inherited disorder of fat metabolism. It is also known as familial chylomicronemia due to apo C-II deficiency or hyperlipoproteinemia type Ib. In this condition, the body cannot properly break down certain fats (triglycerides) in the blood because it lacks a key protein called apolipoprotein C-II. This protein normally activates an enzyme called lipoprotein lipase, which is responsible for clearing fat particles (chylomicrons and very low-density lipoproteins) from the bloodstream. Without functioning apo C-II, triglyceride leve
How is Familial apolipoprotein C-II deficiency inherited?
Familial apolipoprotein C-II deficiency follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
Are there clinical trials for Familial apolipoprotein C-II deficiency?
Yes — 1 recruiting clinical trial is currently listed for Familial apolipoprotein C-II deficiency on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Familial apolipoprotein C-II deficiency?
1 specialists and care centers treating Familial apolipoprotein C-II deficiency are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.